Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kuhl U, Maisch B, McKenna WJ et al (2008) Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29:270–276. https://doi.org/10.1093/eurheartj/ehm342

Article  PubMed  Google Scholar 

Maron BJ, Rowin EJ, Maron MS (2018) Global burden of hypertrophic cardiomyopathy. JACC Heart Fail 6:376–378. https://doi.org/10.1016/j.jchf.2018.03.004

Article  PubMed  Google Scholar 

Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA et al (2023) 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 44:3503–3626. https://doi.org/10.1093/eurheartj/ehad194

Article  CAS  PubMed  Google Scholar 

Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P et al (2020) 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 76:e159–e240. https://doi.org/10.1016/j.jacc.2020.08.045

Article  PubMed  Google Scholar 

Zhang Y, Adamo M, Zou C, Porcari A, Tomasoni D, Rossi M, Merlo M, Liu H, Wang J, Zhou P et al (2024) Management of hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). https://doi.org/10.2459/JCM.0000000000001616

Article  PubMed  Google Scholar 

Bertero E, Chiti C, Schiavo MA, Tini G, Costa P, Todiere G, Mabritto B, Dei LL, Giannattasio A, Mariani D et al (2024) Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population. Eur J Heart Fail 26:59–64. https://doi.org/10.1002/ejhf.3120

Article  CAS  PubMed  Google Scholar 

Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, Garberich RF, Link MS, Chan RHM, Lesser JR, Maron BJ (2016) Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 67:1399–1409. https://doi.org/10.1016/j.jacc.2016.01.023

Article  PubMed  Google Scholar 

Ammirati E, Contri R, Coppini R, Cecchi F, Frigerio M, Olivotto I (2016) Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail 18:1106–1118. https://doi.org/10.1002/ejhf.541

Article  PubMed  Google Scholar 

Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Ostman-Smith I, Clarke K, Watkins H (2003) Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 41:1776–1782. https://doi.org/10.1016/s0735-1097(02)03009-7

Article  CAS  PubMed  Google Scholar 

Psotka MA, Gottlieb SS, Francis GS, Allen LA, Teerlink JR, Adams KF Jr, Rosano GMC, Lancellotti P (2019) Cardiac calcitropes, myotropes, and mitotropes: JACC review topic of the week. J Am Coll Cardiol 73:2345–2353. https://doi.org/10.1016/j.jacc.2019.02.051

Article  PubMed  Google Scholar 

Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A et al (2010) Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122:1562–1569. https://doi.org/10.1161/CIRCULATIONAHA.109.934059

Article  CAS  PubMed  Google Scholar 

Coats CJ, Pavlou M, Watkinson OT, Protonotarios A, Moss L, Hyland R, Rantell K, Pantazis AA, Tome M, McKenna WJ et al (2019) Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial. JAMA Cardiol 4:230–235. https://doi.org/10.1001/jamacardio.2018.4847

Article  PubMed  PubMed Central  Google Scholar 

Hundertmark M, Siu AG, Matthews V, Lewis AJ, Grist JT, Patel J, Chamberlin P, Sarwar R, Yavari A, Frenneaux MP et al (2022) A phase 2a trial investigating ninerafaxstat – a novel cardiac mitotrope for the treatment of diabetic cardiomyopathy (IMPROVE-DiCE). Eur Heart J 43(Supplement_2):ehac544.246. https://doi.org/10.1093/eurheartj/ehac544.246

Maron MS, Mahmod M, Abd Samat AH, Choudhury L, Massera D, Phelan DMJ, Cresci S, Martinez MW, Masri A, Abraham TP, Adler E, Wever-Pinzon O, Nagueh SF, Lewis GD, Chamberlin P, Patel J, Yavari A, Dehbi HM, Sarwar R, Raman B, Valkovič L, Neubauer S, Udelson JE, Watkins H (2024) Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 83(21):2037–2048. https://doi.org/10.1016/j.jacc.2024.03.387

Article  CAS  PubMed  Google Scholar 

Spertus JA, Jones PG, Sandhu AT, Arnold SV (2020) Interpreting the Kansas City cardiomyopathy questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol 76:2379–2390. https://doi.org/10.1016/j.jacc.2020.09.542

Article  PubMed  Google Scholar 

Mendes JL, Dos Santos CM, Sousa-Pinto B (2024) Assessment of patient-reported outcomes measures in heart failure: a systematic review. Heart Fail Rev. https://doi.org/10.1007/s10741-024-10404-y

Article  PubMed  Google Scholar 

Metra M, Tomasoni D, Adamo M, Bayes-Genis A, Filippatos G, Abdelhamid M, Adamopoulos S, Anker SD, Antohi L, Bohm M et al (2023) Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 25:776–791. https://doi.org/10.1002/ejhf.2874

Article  PubMed  Google Scholar